WALTHAM, Mass.--(BUSINESS WIRE)--April 6, 2006--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical compounds to treat cancer and certain ophthalmologic diseases, will announce its first quarter 2006 results on Wednesday, April 26, 2006 prior to the opening of the NASDAQ Stock Market, followed by a conference call at 10:00 a.m. EST. OXiGENE’s President and Chief Executive Officer, Frederick Driscoll, Chief Financial Officer, James Murphy and Chief Scientific Officer, David Chaplin, Ph.D., will host the call.
